FTSV News and Press, Forty Seven Inc. From 03/14/20

By Daniel Shvartsman It's been quite a week, and really quite a 3-week stretch since February 21st. A bear market is here, COVID-19 has infected thousands of people and affected markets and events around the world. There are many fundamental battles out there to be waged and steps to be ta...

NEW YORK, NY / ACCESSWIRE / March 12, 2020 / Juan Monteverde , founder and managing partner at Monteverde & Associates PC , a national securities firm headquartered at the Empire State Building in New York City, is investigating: Franklin Financial Network, Inc. (NYSE: FSB ) ...

NEW YORK, NY / ACCESSWIRE / March 12, 2020 / Halper Sadeh LLP, a global investor rights law firm, continues to investigate whether the following proposed mergers are fair to shareholders. Halper Sadeh LLP may seek increased consideration, additional disclosures and information concerning the...

by Daniel Shvartsman We've had periods of sustained uncertainty in the post financial crisis world, whether they be the debt ceiling 'negotiations' of 2011, the bottom falling out for oil in 2014, the thrashing of January/February 2016, or the near-miss of Q4 2018. But I can't remember an ...

NEW YORK, March 11, 2020 (GLOBE NEWSWIRE) -- Forty Seven, Inc. (NASDAQ:FTSV) Lifshitz & Miller announces investigation into possible breach of fiduciary duties in connection with the sale of FTSV to Gilead Sciences, Inc. for $95.50 per share. If you are a FTSV invest...

Forty Seven ( FTSV -0.2% ) will collaborate with Rocket Pharmaceuticals ( RCKT -11.3% ) to pursue proof-of-concept for the combination of its anti-cKIT antibody FSI-174, a conditioning regimen, and the latter's ex vivo lentiviral hematopoietic stem cell gene therapy RP-L102 in pediat...

MENLO PARK, Calif. and NEW YORK, March 11, 2020 (GLOBE NEWSWIRE) -- Forty Seven, Inc. (Nasdaq: FTSV) and Rocket Pharmaceuticals, Inc. (Nasdaq: RCKT) announced today that they have entered into a research collaboration to pursue clinical proof-of-concept for Forty Seven’s novel antibo...

Merger activity increased last week with four new deals announced and two deals closing. Out of the four deals announced, three were cash deals and one was an all-stock deal. The acquisition of Forty Seven ([[FTSV]]) by Gilead Sciences ([[GILD]]) was the first deal announced last week. FTSV ...

Background According to a recent study by Gartner, average duration to finalize a merger or acquisition from the time of public announcement has risen more than 30 percent in the last decade. Gartner analyzed more than 23000 deals among S&P1200 companies since 2010 to come up with th...

It's hard to swim against the current. But it's not impossible to do so. Most stocks have fallen hard in the current market correction that was initially caused by worries about the coronavirus and is now being worsened by plunging oil prices. There are exceptions, though. Three profitable heal...